搜索
Organon & Co
OGN添加自选
13.550USD
+0.005+0.04%
收盘 07-31 16:00（美东）报价延迟15分钟
3.56B总市值
14.35市盈率 TTM
关于 Organon & Co 公司
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Organon & Co简介
公司代码OGN
公司名称Organon & Co
上市日期May 14, 2021
CEOMorrissey (Joseph T)
员工数量10000
证券类型Ordinary Share
年结日May 14
公司地址30 Hudson Street
城市JERSEY CITY
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编07302
电话15514306000
网址https://www.organon.com/
公司代码OGN
上市日期May 14, 2021
CEOMorrissey (Joseph T)
Organon & Co公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Cynthia M. Patton
Ms. Cynthia M. Patton
Independent Director
Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
常见问题
Organon & Co的前五大股东是谁？
Organon & Co 的前五大股东如下：Mr. Matthew M. (Matt) Walsh
有多少机构持有Organon & Co(OGN)的股份？
截至2026Q1，共有1398家机构持有Organon & Co的股份，合计持有的股份价值约为239.27M，占公司总股份的91.12%。与2025Q4相比，机构持股有所增加，增幅为-3985201.00。
哪个业务部门对Organon & Co的收入贡献最大？
在2026Q1，Women’s Health业务部门对Organon & Co的收入贡献最大，创收1.75B，占总收入的28.19%。